Department of Pathology, University of Virginia, Charlottesville, VA, USA.
Cell Mol Immunol. 2022 Jan;19(1):14-22. doi: 10.1038/s41423-021-00734-4. Epub 2021 Jul 19.
The substantial advances attained by checkpoint blockade immunotherapies have driven an expansion in the approaches used to promote T cell access to the tumor microenvironment to provide targets for checkpoint immunotherapy. Inherent in any T cell response to a tumor antigen is the capacity of dendritic cells to initiate and support such responses. Here, the rationale and early immunobiology of CD40 as a master regulator of dendritic cell activation is reviewed, with further contextualization and appreciation for the role of CD40 stimulation not only in cancer vaccines but also in other contemporary immune-oncology approaches.
检查点阻断免疫疗法取得了重大进展，推动了促进 T 细胞进入肿瘤微环境以提供检查点免疫疗法靶点的方法的扩展。在 T 细胞对肿瘤抗原的任何反应中，树突状细胞启动和支持这种反应的能力都是内在的。在这里，我们回顾了 CD40 作为树突状细胞激活的主调节剂的基本原理和早期免疫生物学，并进一步了解了 CD40 刺激不仅在癌症疫苗中而且在其他当代免疫肿瘤学方法中的作用。
